Antihormonal Cancer Therapies: Leading Brands Strive to Minimize Generic Sales Erosion

Antihormonal cancer therapies are used predominantly in the treatment of breast and prostate cancers. The high incidence of these tumors translates into a significant commercial potential for drug developers. The antihormonal therapy cancer brands generated $7 billion in the seven major pharmaceutical markets in 2009.

Scope

• In-depth analysis of the current and future antihormonal therapies market in the US, five European countries and Japan, plus a rest of world snapshot.
• Antihormonal therapy sales forecasts for brands and generics from 2009 to 2019.
• Assessment of the leading cancer brands and drug classes, and key success factors within this sector.
• Evaluation of the strategies of leading players in the antihormonals market.

Datamonitor. Contains 111 pages and 76 tables/figures